BioTime reports additional data for Renevia facial lipoatrophy device

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported long-term data from a European pivotal trial of Renevia to treat HIV-associated lipoatrophy, which the company said is a severe form of lipoatrophy

Read the full 290 word article

How to gain access

Continue reading with a
two-week free trial.